Clinical Trial Update: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating brentuximab vedotin in combination with lenalidomide for stage IB-IVB relapsed or refractory T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Cutaneous T-cell Lymphoma
• Lymphomatoid Papulosis

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Revlimid (lenalidomide)

Snippet

Sponsor: John Reneau | Conditions: Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Status: COMPLETED